Light Mode
$0.5941 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.5941
-0.33 (-35.42%) / 6M
Momentum, market sentiment, and recent alerts
CTOR reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -64.4%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
No peer group available for this symbol.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.